Arkfeld Daniel G, Rubenstein Elyse
Division of Rheumatology, Keck School of Medicine, University of Southern California, HMR 711, 2011 Zonal Ave., Los Angeles, CA 90033, USA.
Adv Drug Deliv Rev. 2005 May 25;57(7):939-44. doi: 10.1016/j.addr.2005.02.001. Epub 2005 Apr 20.
The number of new medications to treat and even prevent arthritis and osteoporosis has expanded dramatically in recent years. Where once there were only surgical options to treat such end-stage diseases, there are now treatments targeted at the early steps in musculoskeletal pathophysiology. The use of different modalities to maximize drug access to specific bone tissues has created a golden opportunity for mechanistic studies in drug delivery systems for treating osteoporosis and other musculoskeletal diseases. This theme issue provides a timely analysis of the challenges and accomplishments in delivering medicine to the target sites in the musculoskeletal system and also provides a preview of what may come in the future for musculoskeletal medicine. As the number of animal studies and clinical trials is on the rise, the possibility to prevent or even cure the aforementioned disorders has never been closer.
近年来，用于治疗甚至预防关节炎和骨质疏松症的新型药物数量大幅增加。过去，治疗此类终末期疾病只有手术选择，而现在有了针对肌肉骨骼病理生理学早期阶段的治疗方法。利用不同方式最大限度地使药物进入特定骨组织，为治疗骨质疏松症和其他肌肉骨骼疾病的药物递送系统的机制研究创造了绝佳机会。本期专题及时分析了将药物递送至肌肉骨骼系统靶位点所面临的挑战与取得的成就，还展望了肌肉骨骼医学的未来发展。随着动物研究和临床试验数量的不断增加，预防甚至治愈上述疾病的可能性从未如此之近。
